Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2004

View Archived Issues

A sustained-release formulation of lanreotide shows efficacy in acromegaly

Good safety and pharmacokinetic profile of intranasal PYY3-36 in healthy volunteers

Oralin reported to improve mealtime glycemic control in type 2 diabetes

Comparison of sleep induction with melatonin, zaleplon, zopiclone and temazepam

Elan submits Prialt NDA amendment

Remoxy results demonstrate Oradur utility

ZymoGenetics licenses to Novo Nordisk rights to IL-28A, IL-29 and IL-31

FDA approval of NeutroSpec for diagnosis of appendicitis

ViraGen licenses Oxford BioMedica's LentiVector gene delivery technology

AltaRex signs distribution agreement with Dompe

sBLA filed for Bexxar

NeoRx files IND for phase II study of STR in metastatic breast cancer

IDEA receives milestone for progression of targeted pain therapeutic

Second clinical trial evaluates trans-NV-04

Pharming and Esteve reach agreement on rhC1INH

NexMed and Schering AG sign Alprox-TD agreement

U.S. phase II study of FM-VP4 planned for next year

Pharmion launches Vidaza

Forest and PAION enter agreement for desmoteplase in U.S. and Canada

Guidant and Miravant to collaborate on cardiovascular PDT development

Dosing commences in phase III trial of TransMID for glioblastoma multiforme

Positive opinion handed down in Europe for Protelos

Wilzin recommended for approval in Europe for Wilson's disease

Novel DPP-IV inhibitors claimed by Boehringer Ingelheim

FKBP12 ligands for neurodegenerative diseases in early development at Taisho

Boehringer Ingelheim patent describes series of cytokine inhibitors

Modulators of tyrosine kinase-mediated signal transduction disclosed in patent

PDE4 inhibitors prepared and tested at elbion

Gastric and intestinal protectants claimed in Altana patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...